Kevin Church Athira Pharma, Inc. (ATHA) insider trading activity

ATHA Quotes by TradingView

Kevin Church is CHIEF SCIENTIFIC OFFICER of Athira Pharma, Inc.. Currently has a direct ownership of 168,901 shares of ATHA, which is worth approximately $64,182. The most recent transaction as insider was on Jul 01, 2025, when has been sold 8,526 shares (Common Stock) at a price of $0.29 per share, resulting in proceeds of $2,472. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 169K
29.17% 3M change
98.22% 12M change
Total Value Held $64,182

KEVIN CHURCH Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 01 2025
SELL
Open market or private sale
$2,472 $0.29 p/Share
8,526 Reduced 4.81%
168,901 Common Stock
Jun 30 2025
BUY
Exercise of conversion of derivative security
-
36,666 Added 17.13%
177,427 Common Stock
May 19 2025
BUY
Grant, award, or other acquisition
$2,300 $0.23 p/Share
10,000 Added 6.63%
140,761 Common Stock
Jan 02 2025
SELL
Open market or private sale
$4,765 $0.56 p/Share
8,510 Reduced 6.11%
130,761 Common Stock
Dec 31 2024
BUY
Exercise of conversion of derivative security
-
36,667 Added 20.84%
139,271 Common Stock
Nov 18 2024
BUY
Grant, award, or other acquisition
$5,456 $0.55 p/Share
9,920 Added 8.82%
102,604 Common Stock
Sep 05 2024
SELL
Open market or private sale
$1,439 $0.57 p/Share
2,525 Reduced 2.65%
92,684 Common Stock
Sep 03 2024
BUY
Grant, award, or other acquisition
-
10,000 Added 9.5%
95,209 Common Stock
May 20 2024
BUY
Grant, award, or other acquisition
$6,637 $1.34 p/Share
4,953 Added 5.49%
85,209 Common Stock
Nov 20 2023
BUY
Grant, award, or other acquisition
$4,551 $1.34 p/Share
3,397 Added 4.47%
72,668 Common Stock
May 18 2023
BUY
Grant, award, or other acquisition
$1,949 $2.41 p/Share
809 Added 1.15%
69,271 Common Stock
Mar 24 2023
BUY
Exercise of conversion of derivative security
$8,653 $1.35 p/Share
6,410 Added 8.56%
68,462 Common Stock
Jan 05 2023
SELL
Open market or private sale
$7,018 $2.91 p/Share
2,412 Reduced 2.92%
80,256 Common Stock
Jan 04 2023
BUY
Grant, award, or other acquisition
-
10,000 Added 10.79%
82,668 Common Stock
Nov 18 2022
BUY
Grant, award, or other acquisition
$1,800 $2.74 p/Share
657 Added 1.05%
62,052 Common Stock
Oct 28 2022
BUY
Exercise of conversion of derivative security
$4,995 $1.35 p/Share
3,700 Added 5.68%
61,395 Common Stock
Jun 23 2022
SELL
Open market or private sale
$7,032 $2.69 p/Share
2,614 Reduced 4.33%
57,695 Common Stock
Jun 22 2022
BUY
Grant, award, or other acquisition
-
10,000 Added 14.22%
60,309 Common Stock
Jun 08 2022
BUY
Exercise of conversion of derivative security
$3,375 $1.35 p/Share
2,500 Added 4.73%
50,309 Common Stock
May 18 2022
BUY
Grant, award, or other acquisition
$1,716 $7.06 p/Share
243 Added 0.51%
47,809 Common Stock
Feb 18 2022
BUY
Exercise of conversion of derivative security
$3,751 $1.19 p/Share
3,152 Added 6.21%
47,566 Common Stock
Nov 18 2021
BUY
Grant, award, or other acquisition
$1,201 $12.51 p/Share
96 Added 0.22%
44,414 Common Stock
Jun 08 2021
BUY
Exercise of conversion of derivative security
$3,278 $1.04 p/Share
3,152 Added 6.67%
44,133 Common Stock
KC

Kevin Church

CHIEF SCIENTIFIC OFFICER
Bothell, WA

Track Institutional and Insider Activities on ATHA

Follow Athira Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATHA shares.

Notify only if

Insider Trading

Get notified when an Athira Pharma, Inc. insider buys or sells ATHA shares.

Notify only if

News

Receive news related to Athira Pharma, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ATHA